| Management target | EBITDA Year 2 |
|---|
| Revenue growth | 9% YoY growth in Q1 FY27. |
|---|---|
| Margins | EBITDA margin expanded 241 bps YoY to 23.2%. |
| Demand visibility | Strong, driven by higher MR productivity and key brand strength. |
| Management confidence | High; citing sustained traction and disciplined capital allocation. |
Growth
Q1FY27 Revenue reached ₹822 Mn (+8.8% YoY); Operating EBITDA rose to ₹191 Mn (+21.4% YoY) with margins at 23.2%.
Outlook
Targeting ~₹100 Mn EBITDA from Aequitas by Year 2; focuses on sustaining profitable growth through hospital channel expansion.
Risks
Potential macro-economic shifts, regulatory trends, and competitive pressures within the pharmaceutical industry.
Last quarter's promises, checked
Delivered
- Guided double-digit growth → delivered 14.2% in Q4 (= BEAT)
- Guided 1.5x IPM growth → delivered 1.35x (14.2% vs 10.5% IPM) (= BEAT)
- Guided 9-10 new launches/SKUs for FY26 → delivered 9 (6 products + 3 SKUs) (= BEAT)
Partly delivered
- Guided FY26 revenue growth 12-14% → delivered 7% (= MISS)
Investor Presentation filed with NSE, NSE: JAGSNPHARM. Summary written with AI assistance from the document.
Jagsonpal Pharmaceuticals Ltd: key numbers
- Share price
- ₹236.58
- Market cap
- ₹1,560 Cr
- Revenue (annual)
- ₹287.2 Cr
- Net profit (annual)
- ₹43.08 Cr
- P/E (TTM)
- 34.3×Sector 47.4×
- Promoter holding
- 69.05%+1.16% QoQ
- FII holding
- 2.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jagsonpal Pharmaceuticals Ltd
All →Jagsonpal Pharmaceuticals Acquisition Worth ₹46.7 Cr
Jagsonpal Pharmaceuticals Ltd will acquire the Wellness Portfolio of Group Pharmaceuticals Ltd. The transaction involves a total consideration capped at ₹46.7 Crore.
- Value
- ₹46.70 Cr
Jagsonpal Pharmaceuticals Annual General Meeting
Jagsonpal Pharmaceuticals held its 47th Annual General Meeting on September 18, 2026. Shareholders transacted business including adoption of financial statements and director appointments.
Jagsonpal Pharmaceuticals Business Update
Jagsonpal Pharmaceuticals Ltd has filed its Business Responsibility and Sustainability Report for the financial year 2025-26. This report forms part of its annual report.
Jagsonpal Pharmaceuticals Annual General Meeting
Jagsonpal Pharmaceuticals Ltd has issued the notice for its 47th Annual General Meeting, scheduled for September 18, 2026, alongside the Annual Report for FY 2025-26.
Jagsonpal Pharmaceuticals Other Announcement
The company informed shareholders without registered email addresses of the web-link to access the 2025-26 Annual Report and AGM Notice, per Regulation 36(1)(b).
Jagsonpal Pharmaceuticals Employee Stock Options
Jagsonpal Pharmaceuticals Limited allotted 27,950 equity shares following the exercise of employee stock options. This increases the company's total paid-up share capital to Rs. 13.19 Crore.